atezolizumab
roche,neoimmunetech
['atezo', 'neoimmunetech']
today, we are pleased to announce that our final poster #154 at #asco presents pi data evaluating for the 1st time, the combination of #nt-i7 and #atezolizumab in high-risk #skincancers in both checkpoint inhibitor-na ve &amp; checkpoint inhibitor-na ve-relapsed/refractory patients 
NIT is a clinical-stage T cell-focused biotech company, dedicated to expand the horizon of Immuno-Oncology and infectious diseases